Comparing the activity of broad-spectrum beta-lactams in combination with aminoglycosides against VIM-producing <i>Enterobacteriaceae</i>.

ABSTRACT: Metallo-beta-lactamase (MBL)-producing carbapenem-resistant Enterobacteriaceae (CRE) infections continue to pose a serious threat to healthcare. Due to their unique active site, MBLs evade the activity of many novel beta-lactam/beta-lactamase inhibitor combinations, which have been specifically targeted toward those carbapenemases with serine active sites. Furthermore, resistance to most, if not all, other clinically relevant antimicrobial classes leaves few reliable therapeutic options. Combination therapy has thus played a vital role in the treatment of MBL-producing CRE infections. In this study, we utilized the static time-kill assay to investigate clinically relevant concentrations of cefepime, piperacillin-tazobactam, and meropenem alone and in combination with either amikacin

SUBMITTER: Clark JA 

PROVIDER: S-EPMC11448446 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature